Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.200
-0.015 (-6.76%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Virax Biolabs Group Cash Flow Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Net Income | -5.64 | -6.06 | -6.73 | -5.46 | -1.71 | -0.65 | Upgrade
|
| Depreciation & Amortization | 0.39 | 0.33 | 0.1 | - | - | - | Upgrade
|
| Other Amortization | 0.02 | 0.01 | - | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 0.39 | - | - | - | Upgrade
|
| Stock-Based Compensation | 0.38 | 0.37 | 1.01 | 1.75 | 0.29 | - | Upgrade
|
| Other Operating Activities | -0.14 | 0.16 | 0.1 | -0.29 | -0.03 | 0 | Upgrade
|
| Change in Accounts Receivable | 0 | - | - | - | 0 | -0 | Upgrade
|
| Change in Inventory | 0.07 | -0.03 | -0.06 | 0.02 | 0 | -0.02 | Upgrade
|
| Change in Accounts Payable | -0.32 | 0.47 | -0.57 | 0.03 | 0.64 | 0.08 | Upgrade
|
| Change in Unearned Revenue | - | - | -0.04 | 0.04 | - | - | Upgrade
|
| Change in Other Net Operating Assets | -0.16 | 0.19 | -0.45 | -0.28 | 0 | - | Upgrade
|
| Operating Cash Flow | -5.41 | -4.56 | -6.25 | -4.18 | -0.81 | -0.59 | Upgrade
|
| Capital Expenditures | -0.5 | -0.6 | -0.95 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | -0.21 | -0.18 | - | - | Upgrade
|
| Investing Cash Flow | -0.5 | -0.6 | -1.16 | -0.18 | - | - | Upgrade
|
| Short-Term Debt Issued | - | - | - | 0.49 | 0.29 | 0.18 | Upgrade
|
| Total Debt Issued | - | - | - | 0.49 | 0.29 | 0.18 | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.17 | -0.45 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -0.11 | -0.06 | - | - | - | Upgrade
|
| Total Debt Repaid | -0.11 | -0.11 | -0.22 | -0.45 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -0.11 | -0.11 | -0.22 | 0.03 | 0.29 | 0.18 | Upgrade
|
| Issuance of Common Stock | 2.07 | 5.91 | 1.87 | 13.65 | 0.52 | 0.4 | Upgrade
|
| Financing Cash Flow | 1.96 | 5.81 | 1.65 | 13.69 | 0.81 | 0.59 | Upgrade
|
| Net Cash Flow | -3.94 | 0.64 | -5.76 | 9.33 | 0 | -0 | Upgrade
|
| Free Cash Flow | -5.9 | -5.17 | -7.2 | -4.18 | -0.81 | -0.59 | Upgrade
|
| Free Cash Flow Margin | -197677.16% | -81621.64% | -4602.71% | -48823.35% | - | -476.65% | Upgrade
|
| Free Cash Flow Per Share | -1.29 | -1.39 | -3.59 | -3.93 | -0.85 | -2.45 | Upgrade
|
| Levered Free Cash Flow | -3.54 | -3.25 | -4.79 | -2.73 | -0.25 | -0.23 | Upgrade
|
| Unlevered Free Cash Flow | -3.5 | -3.21 | -4.78 | -2.72 | -0.24 | -0.21 | Upgrade
|
| Change in Working Capital | -0.4 | 0.63 | -1.12 | -0.18 | 0.64 | 0.06 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.